In the future, identifying the molecular profile of TGFβ1 sensitive NSCLC lines and exploring the effects of TGFβ1 on lymphangiogenesis in vivo will lead to a better understanding of the role of TGFβ1 in lung cancer progress and eventually to TGFβ pathway inhibitors that could be used for clinical treatment. This evidence concerns the gene TGFB1 and lung carcinoma.